Australia markets open in 16 minutes

Nuvectis Pharma, Inc. (NVCT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.52+0.06 (+0.80%)
At close: 04:00PM EST
7.52 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.46
Open7.32
Bid3.25 x 4000
Ask7.72 x 800
Day's range7.20 - 7.66
52-week range6.20 - 18.65
Volume86,514
Avg. volume77,277
Market cap130.296M
Beta (5Y monthly)0.14
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

    Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences: Event Oppenheimer 34th Annual Healthcare Life Sciences Conference Dat

  • GlobeNewswire

    Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

    Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences: Event Oppenheimer 34th Annual Healthcare Life Sciences Conference Dat

  • GlobeNewswire

    Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows: Date Monday, January 08, 2024 Time 04:30 P